secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2025-04-24T23:59:59+00:00
Accession:  0001645113-25-000009
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure Q1 revenue $155M (+12% YoY), net loss $34.3M; CE Mark for Optune Lua NSCLC
--------------------------------------------------------------------------------

- Revenue $155M, +12% YoY; net loss $34.3M ($0.31 loss per share); adj. EBITDA -$5.0M; cash $929M.
- Active patients 4,268; Optune Gio active patients +9% to 4,162; Optune Lua patients 106 (62 NSCLC, 44 MPM).
- CE Mark approved for Optune Lua with immune checkpoint inhibitors or docetaxel in metastatic NSCLC after platinum progression.
- Tariff risk: up to $11M if tariffs resume post-90-day pause; up to $8M if pause extended; monitoring mitigation.
- PANOVA-3 Phase 3 pancreatic cancer results accepted as late-breaking abstract at ASCO 2025; milestones H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511325000009/0001645113-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511325000009/nvcr-20250424.htm
  HTML page:      https://secwatch.observer/filing/0001645113-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer